Threshold Pharma (THLD) – StreetInsider.com Reports
-
Threshold Pharma (THLD) Confirms 1st Patient Dosed in Immunotherapy Clinical Trial of Evofosfamide & Ipilimumab
-
Threshold Pharma (THLD) Sells TH-3424 to OBI Pharma
-
Threshold Pharma (THLD) to Merge with Molecular Templates
-
Unusual 11 Mid-Day Movers 9/30: (NVFY) (AUPH) (ITUS) Higher; (VEC) (THLD) (DCTH) Lower
-
Threshold Pharma (THLD) to Discontinue Tarloxotinib Development; Will Refocus Resources
-
Threshold Pharma (THLD) Says Two Studies Didn't Meet Activity Thresholds, Plans Workforce Reduction
-
Threshold Pharma (THLD) Regains Nasdaq Listing Compliance
-
Threshold Pharma (THLD) Reports Q2 Loss of $0.10/Share
-
Threshold Pharma (THLD) Shares Pop to Highs
-
Threshold Pharma (THLD) Climbs to Session High
-
Preliminary Russell 3000 Additions and Deletions
-
Threshold Pharma (THLD) Receives Prelim. FDA Comments on Special Meeting; Says Evofosfamide Phase 2 Data Not Enough for NDA
-
Threshold Pharma (THLD) Names Stew Kroll as COO
-
Threshold Pharma (THLD) Updates on Evofosfamide Program; Key Licensing Terms Forged with Merck KGaA
-
Pre-Open Stock Movers 12/21: (NTWK) (AVEO) (ERIC) Higher; (NGLS) (THLD) (FCXM) Lower (more...)
-
Threshold Pharma (THLD) to Reduce Workforce
-
Notable 52-Week Highs and Lows 12/7: (SWHC) (MNGA) (KR) High; (KMI) (THLD) (VNR) Low
-
Unusual 11 Mid-Day Movers 12/7: (GMCR) (XBIT) (GAI) Higher; (THLD) (BLUE) (VNR) Lower
-
Cowen Downgrades Threshold Pharmaceuticals (THLD) to Market Perform
-
Pre-Open Stock Movers 12/07: (GMCR) (SODA) (PBY) Higher; (THLD) (BLUE) (AGIO) (CMG) Lower (more...)
-
Stifel Downgrades Threshold Pharmaceuticals (THLD) to Hold
-
Threshold Pharma (THLD) Says Evofosfamide Studies Did Not Meet Primary Endpoints
-
Threshold Pharma (THLD), Merck (MRK) Enter Co-Promotion Agreement for Evofosfamide
-
Threshold Pharma (THLD) Announces Positive Preclinical Data for Tarloxotinib in EGFR TKIs
-
Threshold Pharma (THLD) Files $200M Mixed Shelf
-
Threshold Pharma (THLD) Tops Q3 EPS by 5c
-
Threshold Pharma (THLD) Receives Two U.S. Patents Covering Tarloxotinib Bromide
-
Threshold Pharma (THLD) Initiates Tarloxotinib Phase 2 in Recurrent, Metastatic SCCHN or SCCS
-
Threshold Pharma (THLD) Announces Initiation of First Tarloxotinib Phase 2 in EGFR NSCLC
-
Threshold Pharma (THLD) Reports Data on Evofosfamide in Relapsed/Refractory Multiple Myeloma to Be Presented at ASCO
-
Market Wrap: Verizon, You've Got ... an Acquisition!; ITT Education Charged with Fraud; GoDaddy's First Quarterly Report
-
Threshold Pharma (THLD) Announces Merck (MRK) Granted FDA Fast Track Designation for Evofosfamide
-
Threshold Pharma (THLD) Reports Positive Preclinical Data on TH-4000
-
Threshold Pharma (THLD) Posts Q4 Loss of 12c/Share
-
Threshold Pharma (THLD) Prices 8.3M Common, Warrants Offering at $3.62/Unit
-
Threshold Pharmaceuticals (THLD) PT Raised to $15 at Piper Jaffray
-
Threshold Pharmaceuticals (THLD) Reports Phase 1/2 Interim Data on TH-302 Plus Bevacizumab
-
Threshold Pharma (THLD) TH-302 Receives FDA Fast Track Designation
-
Threshold Pharma (THLD) Misses Q3 EPS by 3c
-
Pre-Open Stock Movers 9/22: (VIAS) (SIAL) (CNET) Higher; (CRR) (INVN) (YHOO) Lower (more...)
-
IDMC Recommends Continuation of Threshold Pharma's (THLD) TH-302 Combo Phase 3 as Planned
-
Pre-Open Stock Movers 9/9: (BNNY) (IPAS) (THLD) Higher; (FCEL) (FRAN) (PBY) Lower (more...)
-
After-Hours Stock Movers 9/8: (BNNY) (IPAS) (CTIC) Higher; (PBY) (DOC) (PF) Lower (more...)
-
Cantor Fitzgerald Starts Threshold Pharmaceuticals (THLD) at Buy
-
Notable Analyst Rating Changes 9/5: (IPCI) (CIEN) (BP) Upgraded; (TTWO) (PCLN) (MS) Downgraded
-
Pre-Open Stock Movers 9/5: (BLOX) (HURC) (AMBA) (LOCO) Higher; (REPH) (ZQK) (GPS) Lower (more...)
-
H.C. Wainwright Starts Threshold Pharmaceuticals (THLD) at Buy
-
Threshold Pharma (THLD) Commences TH-302 Phase 1/2 Dosing
-
Threshold Pharma (THLD) Updates on TH-302 Phase 1/2 Ahead of ASCO
-
Threshold (THLD) Data on TH-302 in Glioblastoma and Relapsed/Refractory Multiple Myeloma to Be Presented at ASCO 2014
Back to THLD Stock Lookup